Glaukos' iDose TR Now Commercially Available

Glaukos' iDose TR (travoprost intracameral implant 75 mcg), which uses Celanese’s VitalDose EVA (Ethylene Vinyl Acetate) to provide sustained drug release for the treatment of glaucoma, is now commerically available, according to Celanese.

The iDose TR, which received FDA approval in December, is a first-of-its-kind, prostaglandin analog intracameral implant indicated for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma. The iDose TR procedure, which is approved for one administration per eye, is designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Glaukos has established a wholesale acquisition cost for iDose TR of $13,950 per dose (or implant).

"We're continuing our execution of a methodical and controlled launch over the first half of 2024 focused on robust surgeon training within the glaucoma community. Alongside that, we’ll be focusing on establishing the market access pathway, securing coverage and payment for the iDose TR procedure," Glaukos said in a statement to Eyewire+.

Glaukos uses the VitalDose EVA to create a nanoporous membrane for travoprost delivery in iDose TR. The VitalDose EVA is a platform that can be formulated into a wide range of form factors to suit drug delivery needs for various conditions.

“A clear unmet need exists in ophthalmology for therapies that address non-compliance and reduce the treatment burden for patients,” Cyonna Holmes, global business strategy leader for ophthalmology and RNA at Celanese, said in a company news release. “Our team is excited to support Glaukos as they transform the landscape of glaucoma treatment for millions of patients.”